Biogen’s recent beat-and-raise positions the company for a catalyst-rich H1 2026. Key near-term events — Spinraza PDUFA (Apr 3), Parkinson’s LUMA data (Mar), and a subcutaneous Leqembi decision (May 24) — could materially affect BIIB’s trajectory and investor sentiment.

Biogen (BIIB) surged after a Q4 beat, raised guidance and the FDA accepted a priority filing for a subcutaneous Leqembi formulation with a May 24 PDUFA date. Combined with leadership changes and expanded SPINRAZA approval in Europe, these concrete catalysts are reshaping investor sentiment and could influence liquidity and index relevance.

Biogen’s recent quarterly beat was driven by strong Leqembi and Tysabri sales, yet the company faces near-term pressure from legacy-product declines and its December removal from the Nasdaq‑100. Guidance and liquidity concerns temper optimism, leaving BIIB’s near-term trajectory dependent on new-product momentum and trading-volume recovery.

Biogen (BIIB) jumped on Feb 4 after a short slide, with volume above its 50‑day average as investors positioned ahead of the company’s Feb 6 Q4 2025 earnings. Analysts expect $1.72 EPS and ~$2.21B revenue. Recent institutional increases from Federated Hermes and South Korea’s National Pension Service suggest renewed confidence, but short‑term volatility hinges on guidance and commentary about Biogen’s growth drivers.

Biogen’s recent removal from the Nasdaq‑100, combined with volatile January trading and an upcoming Feb. 6 earnings report, creates near-term catalysts and headwinds for BIIB. This article explains the index impact, trading implications, and what to watch next.

Biogen (BIIB) earned European approval for a high-dose Spinraza regimen on Jan 12, 2026—an outcome that could strengthen its SMA franchise in Europe. With quarterly results due Feb 6 and recent volatile share moves, investors are watching revenue cadence, guidance, and uptake of the new dosing to judge near-term upside.